Pelthos Therapeutics Inc.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
PTHS$8.90-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Deficit
PELTHOS THERAPEUTICS INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT
| Preferred A Shares | Preferred A Shares Par | Preferred C Shares | Preferred C Shares Par | Common Shares | Par | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders’ Deficit | |
|---|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2023 | 600,000 | $60 | — | $— | 390,634 | $39 | $7,074,998 | $(13,519,649) | $(6,444,552) |
| Stock-based compensation | — | — | — | — | — | — | 292,552 | — | 292,552 |
| Issuance cost from common stock issued for extension of bridge loan | — | — | — | — | 8,112 | 1 | 447,778 | — | 447,779 |
| Conversion of preferred stock | (600,000) | (60) | — | — | 49,943 | 5 | 55 | — | — |
| Common stock issued for cash | — | — | — | — | 110,000 | 11 | 5,971,989 | — | 5,972,000 |
| Standby agreement | — | — | — | — | 3,750 | — | — | — | — |
| Recission of common stock | — | — | — | — | (11,113) | (1) | (91,511) | — | (91,512) |
| Transfer of liabilities to Chromocell Corp. for preferred C shares | — | — | 2,600 | — | — | — | 2,153,362 | — | 2,153,363 |
| Common stock issued for conversion of notes | — | — | — | — | 25,350 | 3 | 1,362,818 | — | 1,362,821 |
| Net loss | — | — | — | — | — | — | — | (2,562,300) | (2,562,330) |
| Balance March 31, 2024 | — | $— | 2,600 | $— | $576,676 | $58 | $17,211,041 | $(16,081,979) | $1,130,120 |
| Stock option compensation | — | — | — | — | — | — | 366,503 | — | 366,503 |
| RSU expense | — | — | — | — | — | — | 13,975 | — | 13,975 |
| Shares issued for services | — | — | — | — | 5,647 | 1 | 78,499 | — | 78,500 |
| Net loss | — | — | — | — | — | — | — | (1,771,619) | (1,771,619) |
| Balance June 30, 2024 | — | $— | 2,600 | $— | $582,323 | $59 | $17,671,018 | $(17,853,598) | $(182,521) |
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT
| Preferred A Shares | Preferred A Shares Par | Preferred C Shares | Preferred C Shares Par | Common Shares | Par | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders’ Deficit | |
|---|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2024 | — | $— | 2,600 | $— | 610,389 | $61 | $18,760,872 | $(21,474,987) | $(2,714,054) |
| Stock-based compensation | — | — | — | — | — | — | 403,921 | — | 403,921 |
| Restricted Stock Units expense | — | — | — | — | 4,635 | — | 51,910 | — | 51,910 |
| Shares issued for services | — | — | — | — | 1,692 | — | 30,000 | — | 30,000 |
| Shares issued for cash | — | — | — | — | 1,650 | — | — | — | — |
| Net loss | — | — | — | — | — | — | — | (1,967,611) | (1,967,611) |
| Balance March 31, 2025 | — | $— | 2,600 | $— | 618,366 | $61 | $19,246,703 | $(23,442,598) | $(4,195,834) |
| Stock-based compensation | — | — | — | — | — | — | 341,576 | — | 341,576 |
| Restricted Stock Units expense | — | — | — | — | 4,635 | — | 51,910 | — | 51,910 |
| Shares issued for services | — | — | — | — | 1,389 | — | 20,000 | — | 20,000 |
| Shares issued for conversion of notes | — | — | — | — | 48,938 | 5 | 736,987 | — | 736,992 |
| Stock split | — | — | — | — | (8) | 1 | (1) | — | — |
| Net loss | — | — | — | — | — | — | — | (3,448,939) | (3,448,939) |
| Balance June 30, 2025 | — | $— | 2,600 | $— | 673,320 | $67 | $20,397,175 | $(26,891,537) | $(6,494,295) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.